MedPath

Terazosin

TERAZOSIN CAPSULES, USP

Approved
Approval ID

3822068f-f160-4493-a207-4d75dad6af73

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Dec 7, 2023

Manufacturers
FDA

Bryant Ranch Prepack

DUNS: 171714327

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Terazosin Hydrochloride

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code72162-2183
Application NumberANDA075317
Product Classification
M
Marketing Category
C73584
G
Generic Name
Terazosin Hydrochloride
Product Specifications
Route of AdministrationORAL
Effective DateDecember 11, 2023
FDA Product Classification

INGREDIENTS (11)

TERAZOSIN HYDROCHLORIDEActive
Quantity: 5 mg in 1 1
Code: D32S14F082
Classification: ACTIM
GELATIN, UNSPECIFIEDInactive
Code: 2G86QN327L
Classification: IACT
MAGNESIUM STEARATEInactive
Code: 70097M6I30
Classification: IACT
SODIUM LAURYL SULFATEInactive
Code: 368GB5141J
Classification: IACT
LACTOSE MONOHYDRATEInactive
Code: EWQ57Q8I5X
Classification: IACT
TITANIUM DIOXIDEInactive
Code: 15FIX9V2JP
Classification: IACT
STARCH, CORNInactive
Code: O8232NY3SJ
Classification: IACT
SILICON DIOXIDEInactive
Code: ETJ7Z6XBU4
Classification: IACT
D&C YELLOW NO. 10Inactive
Code: 35SW5USQ3G
Classification: IACT
D&C RED NO. 28Inactive
Code: 767IP0Y5NH
Classification: IACT
FD&C RED NO. 40Inactive
Code: WZB9127XOA
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.